PTEN Back

phosphatase and tensin homolog (mutated in multiple advanced cancers 1)

External References:      Wikipedia GeneCards HUGO COSMIC Google Scholar

NCBI Description of PTEN

This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway.

Community Annotation of PTEN Add / Edit PTEN: Annotations

Added by Agostino Lacroix

0

Sort mutations by: Tumor type  Mutation type  Position  
Straightedge cursor Expand

Figure notes


• "Mouse over" a mutation to see details.
• Missense green saturation indicates evolutionary conservation of the mutated positions.
• Red hashes in protein strip are splice sites.
• Blue-white-red bars are log2 copy ratio distributions (–1 to +1) from Zack et al. (2013).


Legend

PTEN is highly significantly mutated in
Endometrial
UCEC
163 patients (65%)
Glioblastoma multiforme
GBM
90 patients (30%)
combined cohort
PanCan
372 patients (7%)
Kidney clear cell
KIRC
21 patients (5%)
Breast
BRCA
31 patients (3%)
Head and neck
HNSC
11 patients (2%)
PTEN is significantly mutated in
Melanoma
MEL
11 patients (9%)
PTEN is near significance in
Lung squamous cell carcinoma
LUSC
14 patients (7%)
Diffuse large B-cell lymphoma
DLBCL
3 patients (5%)
Colorectal
CRC
8 patients (3%)

Click on a tumor type to see its full list of significant genes.

Data details


Mutation list for PTEN